Clinical Trial

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and and Baricitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-19.
Status change: Recruiting → Active, Not Recruiting 2024-08-22
Trial Details
NCT Number NCT06475820
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
Enrollment 150 participants
Start Date 2023-12-01
Primary Completion 2024-07-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-23